Gyon Technologies Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Gyon Technologies Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-359	Closed	-$271K	–	296
2021 Q4	$271K	Buy	+359	New	+$269K	0.05%	444
2021 Q3	–	Sell	-314	Closed	-$202K	–	377
2021 Q2	$202K	Buy	+314	New	+$191K	0.07%	338
2021 Q1	–	Sell	-715	Closed	-$417K	–	408
2020 Q4	$417K	Buy	715 +106	+17%	+$60.4K	0.14%	195
2020 Q3	$314K	Buy	+609	New	+$308K	0.25%	151

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gyon Technologies Capital Management's BIO Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 359 shares — an estimated $271K sold.

Gyon Technologies Capital Management first reported a position in BIO in Q3 2020 and held it in 4 quarters. The position peaked at $417K in Q4 2020. 515 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

Gyon Technologies Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
Gyon Technologies Capital Management sold 359 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $271K.
Gyon Technologies Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 4 quarters.
Gyon Technologies Capital Management's Bio-Rad Laboratories Class A position peaked at $417K in Q4 2020.
515 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.